Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS study) - Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS study)

Osaka University0 个研究点目标入组 31 人开始时间: 2015年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Type 1 diabetes mellitus 2. Moderate or severe renal dysfunction (eGFR<45 ml/min/1.73m2 or hemodialysis) 3. Severe hepatic insufficiency (AST and/or ALT >3x upper limit of normal) 4. Adrenal insufficiency or pituitary gland dysfunction 5. Malnourishment, starvation, irregular dietary intake, poor dietary intake, debilitating condition or a severe muscle movement 6. Volume depleted patients; concomitant medication such as loop diuretics. 7. Excessive alcohol intake (>60g daily) 8. SGLT2 inhibitors such as dapagliflozin are already administered 9. Contraindication with dapagliflozin 10. Start a new medication of statins, fibratesm ezetimibe or probucol within a month 11. Females who are likely to be pregnant, during pregnancy or lactating 12. Participants in other clinical trials 13. Inability to communicate and comply with all study requirements.

发起方